Affiliations 

  • 1 Pediatric Allergist Private Practice, Angeles Lomas Hospital Huixquilucan Mexican State, Mexico City, Mexico
  • 2 Department of Paediatrics, KK Women's and Children's Hospital, Singapore, Singapore
  • 3 Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece
  • 4 Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
  • 5 Medical School, University of Nicosia, Nicosia, Cyprus
  • 6 Pediatric Allergy Clinic, Pachuca, Mexico
  • 7 Allergy & Immunology Center, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 8 Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong, China
  • 9 Pediatric Department Faculty of Medicine, Children Hospital Cairo University, Cairo, Egypt
  • 10 Department of Pediatrics, Abdul Aziz University Hospital, Jeddah, Saudi Arabia
  • 11 Department of Child Health, Faculty of Medicine, Univesitas Padjadjaran, Bandung, Indonesia
  • 12 R&D, FrieslandCampina, Amersfoort, Netherlands
  • 13 Medical Affairs, Friesland Campina AMEA, Singapore, Singapore
  • 14 Inflammation Repair and Development, National Heart and Lung Institute Imperial College, London, United Kingdom
Front Immunol, 2021;12:608372.
PMID: 34177882 DOI: 10.3389/fimmu.2021.608372

Abstract

The prevalence of food allergy has increased over the last 20-30 years, including cow milk allergy (CMA) which is one of the most common causes of infant food allergy. International allergy experts met in 2019 to discuss broad topics in allergy prevention and management of CMA including current challenges and future opportunities. The highlights of the meeting combined with recently published developments are presented here. Primary prevention of CMA should start from pre-pregnancy with a focus on a healthy lifestyle and food diversity to ensure adequate transfer of inhibitory IgG- allergen immune complexes across the placenta especially in mothers with a history of allergic diseases and planned c-section delivery. For non-breastfed infants, there is controversy about the preventive role of partially hydrolyzed formulae (pHF) despite some evidence of health economic benefits among those with a family history of allergy. Clinical management of CMA consists of secondary prevention with a focus on the development of early oral tolerance. The use of extensive Hydrolysate Formulae (eHF) is the nutrition of choice for the majority of non-breastfed infants with CMA; potentially with pre-, probiotics and LCPUFA to support early oral tolerance induction. Future opportunities are, among others, pre- and probiotics supplementation for mothers and high-risk infants for the primary prevention of CMA. A controlled prospective study implementing a step-down milk formulae ladder with various degrees of hydrolysate is proposed for food challenges and early development of oral tolerance. This provides a more precise gradation of milk protein exposure than those currently recommended.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.